ArQule (ARQL) Getting Somewhat Favorable News Coverage, Accern Reports
Media stories about ArQule (NASDAQ:ARQL) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ArQule earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8614837689103 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Insider Buying: ArQule, Inc. (ARQL) CEO Acquires 16,397 Shares of Stock (americanbankingnews.com)
- BRIEF-Arqule Inc CEO Paolo Pucci buys 19,156 shares of co’s common stock on Sept 5 (ARQL) (markets.businessinsider.com)
- Zacks Investment Research Lowers ArQule, Inc. (ARQL) to Hold (americanbankingnews.com)
- ArQule, Inc. (ARQL) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
ArQule (NASDAQ ARQL) traded up 1.79% on Wednesday, hitting $1.14. The stock had a trading volume of 46,157 shares. The firm’s market cap is $81.13 million. The firm’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.13. ArQule has a 1-year low of $0.92 and a 1-year high of $1.82.
ArQule (NASDAQ:ARQL) last released its quarterly earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same quarter in the previous year, the business posted ($0.07) earnings per share. On average, equities research analysts predict that ArQule will post ($0.43) earnings per share for the current year.
Several research firms have recently issued reports on ARQL. Zacks Investment Research raised ArQule from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Wednesday, August 23rd. ValuEngine cut ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
COPYRIGHT VIOLATION WARNING: “ArQule (ARQL) Getting Somewhat Favorable News Coverage, Accern Reports” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/13/arqule-arql-getting-somewhat-favorable-news-coverage-accern-reports.html.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.